1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Feb 2020
Admin
News Article

Wpd Pharmaceuticals Completed The Acquisition Of Two Pancreatic Cancer Drug Candidates

Wpd Pharmaceuticals Inc., A Clinical Stage Pharmaceutical Company, Provides This Update On The Completed Acquisition Of Exclusive Sublicenses For Two Drug Candidates From Moleculin Biotech, Inc. (Nasdaq: Mbrx) A Leading Global Pharmaceuticals Company Focused On The Treatment Of Highly Resistant Cancers. The Territory Covered By The Patents Includes 30 Countries In Europe And Asia, Including Russia.The Licensed Drug Candidates, Wp1122 And Wp1732, Are Both Considered Promising Potential Therapies For Treating Pancreatic Cancer, Among Other Highly Resistant Tumors. Wp1732 Appears Capable Of A Disproportionately High Accumulation In The Pancreas, Making It A Promising Candidate For Treating Pancreatic Cancer. Wp1122 Is Capable Of Inhibiting Glycolysis, A Process By Which Cells Convert Glucose Into Energy And One On Which Many Tumor Cells Are Known To Be Much More Dependent For Their Survival Than Normal Cells. In Particular, Pancreatic Cancer Is Known To Be Highly Dependent On Glycolysis.The Incidence Of And Number Of Deaths Caused By Pancreatic Cancer Have Been Gradually Rising, Even As The Incidence And Mortality Of Other Common Cancers Have Been Declining. Removal Of The Pancreatic Cancer Tumor Is Currently The Only Chance Of Cure. Unfortunately, 80% To 85% Of Patients Diagnosed With Pancreatic Cancer Are At An Advanced Stage And The Tumor Has Overtaken The Pancreas And Even Surrounding Tissues. Furthermore, Pancreatic Cancer Responds Poorly To Most Chemotherapeutic Agents.Mariusz Olejniczak, Ceo Of Wpd Commented, â

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!